Biotech Values

[poorgradstudent]

Myokardia:

I'm very meh. I spoke to them about a job a couple of years ago and it sure seemed like they were going to walk in the footsteps of Cytokinetics. The section head I spoke to was even a former CYTK guy. The founding story is also similar, with James Spudich having a role in starting both CYTK and MYOK.

They were interested in some cardiomyopathy targets that aren't very exciting at all, and got relatively hand-wavey about how they were going to target them and what it was supposed to achieve. It didn't fill me with confidence that they were indeed looking at a new way to attack and treat this disease.

I'd wait for some data before investing hard-earned money.